ReviewFrontiers in pharmacology2021
Role of Specialized Pro-Resolving Mediators in Neuropathic Pain.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The effects of aerobic exercise on neuroimmune responses in animals with traumatic peripheral nerve injury: a systematic review with meta-analyses.Journal of neuroinflammation · 2023Pooled it
- Effects of Antarctic krill oil on lipid profiles and SPM levels in rats over time.NPJ science of food · 2026Article
- A synergistic multimodality treatment approach to address the key drivers of wound chronicity.Journal of vascular surgery. Venous and lymphatic disorders · 2026Review
- Resolvin D1 accelerates resolution of neuroinflammation by inhibiting microglia activation through the BDNF/TrkB signaling pathway.European journal of medical research · 2025Article
- The Causal Relationship Between Immune Cells and Neuropathic Pain: A Two-Sample Mendelian Randomization Study Based on Genome-Wide Association Analysis.Journal of pain research · 2025Article
- Pain in polycystic ovary syndrome: a comprehensive bedside to bench perspective on an underrecognized symptom.Frontiers in pharmacology · 2025Review
- A Narrative Review of the Dorsal Root Ganglia and Spinal Cord Mechanisms of Action of Neuromodulation Therapies in Neuropathic Pain.Brain sciences · 2024Review
- Blood-Derived Eye Drops for the Treatment of Corneal Neuropathic Pain.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2024Review
- Article
- The Plasticity of Immune Cell Response Complicates Dissecting the Underlying Pathology of Multiple Sclerosis.Journal of immunology research · 2024Review
- Macrophages and microglia in inflammation and neuroinflammation underlying different pain states.Medical review (2021) · 2023Article
- Sphingosine Kinases at the Intersection of Pro-Inflammatory LPS and Anti-Inflammatory Endocannabinoid Signaling in BV2 Mouse Microglia Cells.International journal of molecular sciences · 2023Article
- Pain-resolving immune mechanisms in neuropathic pain.Nature reviews. Neurology · 2023Review
- M2 macrophage polarization: a potential target in pain relief.Frontiers in immunology · 2023Review
- Article
- Aspirin-triggered Resolvin D1 ameliorates activation of the NLRP3 inflammasomeFrontiers in pharmacology · 2023Article
- Application of regulation of reactive oxygen species and lipid peroxidation to disease treatment.Journal of clinical biochemistry and nutrition · 2023Article
- The role of free fatty acid receptor pathways in a selective regulation of TRPA1 and TRPV1 by resolvins in primary sensory neurons.Journal of cellular physiology · 2022Article
- Creating an Optimal In Vivo Environment to Enhance Outcomes Using Cell Therapy to Repair/Regenerate Injured Tissues of the Musculoskeletal System.Biomedicines · 2022Review
- Profiling of fatty acid metabolism in the dorsal root ganglion after peripheral nerve injury.Frontiers in pain research (Lausanne, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammation and neuroinflammation are critical mechanisms in the generation of neuropathic pain that is experienced in several chronic diseases. The aberrant inflammation that triggers this pathophysiologic process can be tracked down to an exacerbated immune response, which establishes a vicious cycle and continuously recruits inflammatory cells by inducing chronic tissue damage. Recently, impairment of the cellular and molecular machinery orchestrated by specialized pro-resolving mediators (SPMs)-i.e., endogenous lipids termed resolvins, protectins, maresins, and lipoxins that confine the inflammatory cascades in space and time during the "resolution of inflammation"-has emerged as a crucial event in the derangement of the inflammatory homeostasis and the onset of chronic inflammation and pain. Indeed, a deviant inflammatory response that is not adequately controlled by the resolution network leads to the overproduction of pro-inflammatory eicosanoids that, opposite to SPMs, lead to neuropathic pain. Interestingly, in the last two decades convincing evidence has demonstrated that SPMs antagonize the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.